Keystone Symposia

Fairmont Banff Springs Floorplan

This meeting took place in 2023


Here are the related meetings in 2024:
Antibodies as Drugs: The Art in Antibody Engineering (C6)

For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Next Generation Antibody Therapeutics: From Discovery to Patient (Q5)


Organizer(s) Pamela M. Holland and James A. Wells
February 19—22, 2023
Fairmont Banff Springs • Banff, AB Canada
Abstract Deadline: Nov 28, 2022
Scholarship Deadline: Nov 28, 2022
Discounted Registration Deadline: Dec 15, 2022

Sponsored by Biogen, Boehringer Ingelheim Pharmaceuticals, Inc., Genmab A/S, GlaxoSmithKline Biologicals and Surface Oncology


Summary of Meeting:
Therapeutic antibodies have become the predominant class of new drugs gaining FDA and have positively impacted the most patients for treating various human diseases, including cancer, autoimmune, and infectious diseases. Over the past 30 years, major technological advances have facilitated the discovery and development of monoclonal antibody therapies, and new strategies are continually emerging to enhance their clinical potential. Though substantial progress has been made, new opportunities and challenges continue to evolve in this rapidly moving field. Multiple advances in antibody technology to expand antibody attributes have already translated into improved clinical activity in multiple therapeutic areas. Yet they also unveil major challenges with respect to target validation, MOA, protein design, development time, and managing increasing costs of antibody manufacturing. The aim of this conference will be to provide a diverse program comprised of academic and industry scientists that addresses the challenges and opportunities relevant to antibody drug discovery and development. Specifically, this conference will focus on 1) target identification and novel discovery platforms, 2) advances in protein engineering to improve functional properties and new antibody modalities and delivery methods and 3) an overview of emerging clinical therapeutics in oncology, infectious disease and autoimmunity/inflammation. We envision this program will offer investigators an overview of antibody therapy development from bench to bedside and also highlight cutting edge technological and clinical advancements of interest to a broad spectrum of scientists.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


The meeting will begin on Sunday, February 19 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Wednesday, February 22 with a closing plenary session from 17:00 to 19:00, followed by a social hour. We recommend return travel on Thursday, February 23 in order to fully experience the meeting.

SUNDAY, FEBRUARY 19

16:00—20:00
Arrival and Registration

Riverview Lounge
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.

Riverview Lounge

MONDAY, FEBRUARY 20

07:00—08:00
Breakfast

Alberta/New Brunswick
08:00—09:00
Welcome and Keynote Address (Joint)

Cascade Ballroom
* Pamela M. Holland, InduPro, USA

* Pablo Umaña, Roche Innovation Center Zürich, Switzerland

* James A. Wells, University of California, San Francisco, USA

Tomoyuki Igawa, Chugai Pharmaceutical, Japan
Conditional Activation of Antibody Therapeutics in the Tumor Microenvironment

09:00—11:15
Conditional Targeting with Multi-Specific Engagers (Joint)

Cascade Ballroom
* Pamela M. Holland, InduPro, USA

* Pablo Umaña, Roche Innovation Center Zürich, Switzerland

Katarina Pance, Epi Biologics, USA
Bispecific Antibodies for Targeted Degradation of Extracellular Proteins

Coffee Break

Wendy Ritacco, AbbVie Bioresearch Center, USA
A Targeted Conditional PSCA-CTLA4 DVD-Ig for Immuno-Oncology: POC in Syngeneic Tumor and Metastasis Models

Edward van der Horst, Sensei Biotherapeutics, USA
Short Talk: SNS-101, A Conditionally Active Anti-VISTA Antibody, Potentiates Anti-tumor Effects of PD-1 Blockade and Displays Favorable Pharmacokinetic and Cytokine Release Characteristics

11:15—17:00
On Own for Lunch

11:15—13:00
Poster Setup

Alberta/New Brunswick
13:00—22:00
Poster Viewing

Alberta/New Brunswick
14:30—16:30
Workshop 1: New Ab Therapeutics and Engineering Platforms

Cascade Ballroom
Yanay Ofran, Biolojic, Israel
A Computationally Designed Selective Agonist/Antagonist anti-IL-2 Antibody Redirects Endogenous Human IL-2 to Enhance Teff Function, while Antagonizing Tregs

Maxwell Stefan, Twist Biosciences, USA
Discovery of Novel Complement component 5a Receptor 1 Antagonistic Antibodies Using a Target-Specific Generated Phage Library

Nazanin Larijani, National Research Council, Canada
CAIX VHH-based Therapies for Specific Targeting of Hypoxic Solid Tumor Areas

Frank J. Beurskens, Genmab, Netherlands
Engineered Mutually-dependent IgG Antibody Combinations that Selectively Act on Cells Co-expressing Two Antigens

Adam Zwolak, Janssen R&D, USA
Mucosal Targeting of Antibodies: Hitchhiking on the Polymeric Ig Receptor

* Christoph Rader, The Scripps Research Institute, USA
Concerted Antibody and Antigen Discovery by Differential Whole-cell Phage Display Selections and Multiomic Target Deconvolution

Malin Jönsson, KTH Royal Institute of Technology, Sweden
CaRA - Calcium-Regulated Affinity Domains with Novel Target Specificities for Enhanced Therapeutic Potential

Lorenzo Maso, NYULMC, USA
Creating MHC-restricted Neoantigens with Covalent Inhibitors that can be Targeted by Immune Therapy

16:30—17:00
Coffee Available

Riverview Lounge
17:00—19:00
Antibody Modality

Cascade Ballroom
Shelley Ackerman, Bolt Biotherapeutics, USA
Remote Presentation: Development of Immune Stimulating Antibody Conjugates to Promote Durable Antitumor Immunity

* John R. Desjarlais, Xencor, Inc., USA
A Variety of Antibody-based Modalities for T Cell Signals 1, 2, and 3

Sai T. Reddy, ETH Zurich, Switzerland
Engineering Synthetic T Cell Receptors for Enhanced Potency and Specificity

Francisco Leon, Provention Bio, Inc, USA
Bi-Specific B Cell Targeting Diabody DART for Gene Therapy, SLE and Other Autoimmune Disorders

17:00—19:00
Immune Synapse and Design of Immune Cell Engagers

Alhambra Ballroom
Michael L. Dustin, University of Oxford, UK
Molecular Insights into the Immune Cell Synapse Relevant to Immune Cell Engagers

Rebecca Chen, Pfizer, Inc., USA
One Size Does Not Fit All: Navigating the Multi-dimensional Space to Optimize T-cell Engaging Bispecific Antibodies

* Daniel S. Chen, Engenuity Life Sciences, USA
Multimeric Engagers: Cytotoxicity, Cytokine Release and the T cell Power Curve

Matthew I. J. Raybould, University of Oxford, UK
Short Talk: Computationally Profiling Peptide:MHC Recognition by T-cell Receptors and T-Cell Receptor-mimetic Antibodies

Raffi Tonikian, AbCellera, Canada
Short Talk: Streamlining T-cell Engager Development with a Diverse Panel of Fully Human CD3-binding Antibodies, Bispecific Engineering Technology, and an Integrated Discovery Engine

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Alberta/New Brunswick
19:30—22:00
Poster Session 1

Alberta/New Brunswick

TUESDAY, FEBRUARY 21

07:00—08:00
Breakfast

Alberta/New Brunswick
08:00—11:00
New Approaches Toward Target Identification

Cascade Ballroom
* Bernd Wollscheid, ETH Zürich, Switzerland
Leveraging Surfaceome Nanoscale Organization for Theranostics

James A. Wells, University of California, San Francisco, USA
Cell Surface Protolysis for Neo-Epitopes

Coffee Break

Niyi Fadeyi, InduPro, USA
A Photocatalytic Toolbox for Cataloging Inherent Protein Proximity at the Membrane Surface

Erica Ollmann Saphire, La Jolla Institute for Immunology, USA
Structural Biology of Viruses Toward Therapeutic Development

Garrett Rappazzo, Adimab LLC, USA
Short Talk: Rapid Engineering of Soluble T Cell Receptors for Enhanced Affinity via a High-throughput Yeast-based Platform

08:00—11:00
Resistance Mechanisms to Immune Cell Engagers

Alhambra Ballroom
Marion Subklewe, LMU University Hospital Munich, Germany
Adaptive Immune Resistance and Checkpoint Inhibiting Trispecific Engagers

* Joaquín Arribas, Vall d'Hebron Institute of Oncology, Spain
IFN-Signaling and Acquired Cancer Cell Resistance to T Cell Engagers

Coffee Break

Katherine Beglinger, Merck & Co., Inc., USA
Engineering a Trispecific T-cell Receptor Engager (TREy) with Increased Potency and Selectivity for Tumor Immunotherapy

Christopher E. Rudd, University of Montreal, Canada
Immune Adaptor SLP-76 Regulates Metabolic and Killing CD8+ T Cells Responses against Tumors

11:00—17:00
On Own for Lunch

11:00—13:00
Poster Setup

Alberta/New Brunswick
13:00—22:00
Poster Viewing

Alberta/New Brunswick
14:30—16:00
Workshop 2: Emerging Approaches to Expand Biologic Therapies

Cascade Ballroom
Benjamin Bell, Merck & Co., Inc., USA
Enzyme Engineering of Human Hyaluronidase-1 for Subcutaneous Delivery of Biologics

* Andrea Imle, BioNTech SE, Germany
HexaBody-CD27 Enhances Proliferation, Cytokine Secretion and Cytotoxic Activity of Activated T cells without Requirement for Fc Gamma Receptor-mediated Crosslinking

Jonathan Back, GlycoEra, Switzerland
Glycoengineered Lysosomal-Targeting Constructs (G-LyTAC) engaging ASGPR: A Novel Class of Targeted Extracellular Proteins Degraders

Noel T. Pauli, Adimab LLC, USA
Efficient Antibody Discovery against Membrane-obligate Drug Targets Utilizing a Yeast-based, Single B cell Cloning Platform

Shaheen Farhadi, Merck & Co., Inc., USA
Targeting Interleukin-12 and -23 Private Receptors with Agonist Antibodies

16:30—17:00
Coffee Available

Riverview Lounge
17:00—19:00
Emerging Costimulatory Therapies in Oncology (Joint)

Cascade Ballroom
* Pablo Umaña, Roche Innovation Center Zürich, Switzerland
Off-the-Shelf Enhanced T Cell Redirection via Tumor-Targeted Costimulatory Agonist and Engager Combinations

Janelle Christine Waite, Regeneron, USA
Tumor-Targeted Costimulation via Bispecific CD28 Antibodies

* Pamela M. Holland, InduPro, USA
Conditional Targeting of CD28 in the Tumor Micorenvironment

Sara Majocchi, Novimmune SA, Switzerland
Tumor and Immune Checkpoint-Dependent CD28 Agonism Using Bispecific Antibodies

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Alberta/New Brunswick
19:30—22:00
Poster Session 2

Alberta/New Brunswick

WEDNESDAY, FEBRUARY 22

07:00—08:00
Breakfast

Alberta/New Brunswick
08:00—11:00
Discovery Platforms

Cascade Ballroom
* Jamie Spangler, Johns Hopkins University, USA
A Suspension-based Cell-cell Interaction Platform for Membrane Protein-targeted Antibody Discovery

Shohei Koide, New York University Langone Health, USA
Targeting Intracellular Proteins with Biologics

Coffee Break

Mart Ustav Jr., Icosagen Cell Factory OÜ, Estonia
Functional Antibodies Against Multi Span Transmembrane Proteins - Revisiting the Warburg Effect in Cancer Cells

Nora Karnowski, Apis Assay Technologies Ltd, Germany
Short Talk: Targeting Highly Homologous Pathogens With Supremely Specific Clickmers

Bhuvaneshwari Shunmuganathan, National university of singapore, Singapore
Short Talk: The Application of Advanced Antibody Engineering Methodologies for Development of Prognostic and Diagnostic Assays for COVID-19

08:00—11:00
Enhancing Immune Engager Safety and Efficacy: Alternative Combination Strategies

Alhambra Ballroom
* Marion Subklewe, LMU University Hospital Munich, Germany

Teemu T. Junttila, Genentech, Inc., USA
Understanding and Addressing Cytokine Release Syndrome from T Cell Engagers

Junyun Lai, Peter MacCallum Cancer Centre, Australia
Stimulating Dendritic Cells to Enhance Epitope Spreading from Synthetic T Cell Redirection

Coffee Break

Nadine van Montfoort, Leiden University Medical Center, Netherlands
Preconditioning the Immune Microenvironment of Excluded Tumors for Bispecific T-Cell Engagers

Nora Philipp, LMU University Hospital Munich, Germany
Short Talk: Bispecific´s Best Buddies: Combinatorial Treatment Strategies to Mitigate T-Cell Exhaustion

Mohosin Sarkar, Evolveimmune Therapeutics, USA
Short Talk: EVOLVE: A Novel Costimulatory T Cell Engager Platform Engineered for the Treatment of Immune Suppressive Solid and Hematologic Cancers

Carston R. Wagner, University of Minnesota, USA
Short Talk: Eradication Of Heterogeneous Tumors By T-Cells Targeted with Combination Bispecific Chemically Self-Assembled Nanorings (CSANs)

Edward Seung, ModeX Therapeutics, USA
Short Talk: A Trispecific Antibody Targeting HER2 and T Cells Inhibits Breast Cancer Growth via CD4 Cells

11:00—17:00
On Own for Lunch

15:00—16:30
Career Roundtable (Joint)

Alhambra Ballroom
Markus G. Manz, University Hospital Zürich, Switzerland

Francisco Leon, Provention Bio, Inc, USA

Jamie Spangler, Johns Hopkins University, USA

16:30—17:00
Coffee Available

Riverview Lounge
17:00—18:45
Emerging Antibody Therapeutics in Infectious Disease

Cascade Ballroom
* James A. Wells, University of California, San Francisco, USA

Christopher O. Barnes, Stanford University, USA
Structural Characterization of Antibody Responses to SARS-CoV-2

Ting Y. Wong, WRAIR, USA
Short Talk: Murine Monoclonal Antibodies against Secreted Staphylococcus Aureus Prothrombin-activating Virulence Factors Induce Macrophage Opsonophagocytosis

Elizabeth Parzych, Wistar Institute, USA
Short Talk: Development of DNA-encoded, Functionally- enhanced Antibody Therapeutics against SARS-CoV-2

Jason Kang, West Virginia University, USA
Short Talk: Monoclonal Antibodies to Lipopolysaccharide Protect against Pseudomonas Aeruginosa Infection

17:00—18:45
Innate Immune Cell Engagers

Alhambra Ballroom
* Markus G. Manz, University Hospital Zürich, Switzerland

Marjolein van Egmond, VU University Medical Center, Netherlands
Bispecific Neutrophil Engagers for Cancer Immunotherapy

Yannis Morel, Innate Pharma, France
Trispecific NK Cell Engagers

Christine Trumpfheller, Roche Glycart, Switzerland
Targeted Myeloid Cell Engagement via Bispecific CD40 Agonists

Hans van der Vliet, Lava Therapeutics, Netherlands
GammaDelta T-Cell Bispecific Engagers

18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)

Cascade Ballroom
18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)

Alhambra Ballroom
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Alberta/New Brunswick

THURSDAY, FEBRUARY 23

08:00—08:00
Departure


*Session Chair †Invited, not yet responded.



Keystone Symposia thanks our Sponsors(s) for generously supporting this meeting:

Biogen Boehringer Ingelheim Pharmaceuticals, Inc.
Genmab A/S GlaxoSmithKline Biologicals
Surface Oncology
 

We gratefully acknowledge additional support from these exhibitors at this conference:

BioLegend, Inc.
Please stop by to meet these exhibitors during the conference.


We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1R13AI172245-01

Funding for this conference was made possible (in part) by 1R13Al172245-01 from the National Institute Of Allergy And Infectious Diseases (NIAID) with co-funding provided by National Center For Advancing Translational Sciences (NCATS). The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.


We gratefully acknowledge additional support for this conference from:

EpiVax, Inc.
Nicoya Lifesciences


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: John Monson, Director of Corporate Relations, Email: johnm@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Josh May, Director, Technology and Digital Media, Email: joshuam@keystonesymposia.org,
Phone:+1 970-262-1179